Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on May 15, 2019. The filing serves to announce the company's financial results for the three-month period ended March 31, 2019. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced via a press release (Exhibit 99.1) but does not contain the detailed financial data within the body of the 8-K itself.
Material Changes
No material changes versus the prior comparable period are detailed in this filing text. The report references the attached press release for the full announcement of results but does not summarize specific variances or trends in this document.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to various factors. It directs investors to the "Risk Factors" section of the company's periodic SEC reports for additional details on contingencies and risks. The company disclaims any obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 15, 2019) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical firm.
- Check subsequent filings for updates on clinical trial progress or capital raise activities.
- Confirm the status of the company's emerging growth company election and its impact on financial reporting standards.